Salinomycin

Last updated
Salinomycin
Salinomycin.png
Names
IUPAC name
(2R)-2-[(5S,6R)-6-[(1S,2S,3S,5R)-5-[(2S,5R,7S,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyl-2-tetrahydropyranyl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-2-hydroxy-1,3-dimethyl-4-oxoheptyl]-5-methyl-2-tetrahydropyranyl]butanoic acid
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.052.974 OOjs UI icon edit-ltr-progressive.svg
E number E716 (antibiotics)
PubChem CID
UNII
  • InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1 X mark.svgN
    Key: KQXDHUJYNAXLNZ-XQSDOZFQSA-N X mark.svgN
  • InChI=1/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1
    Key: KQXDHUJYNAXLNZ-XQSDOZFQBR
  • O=C([C@H]([C@H]([C@@H]([C@]3([H])O[C@]([C@@H](CC)C(O)=O)([H])CC[C@@H]3C)C)O)C)[C@H](CC)[C@@]([C@@H](C)C[C@H]2C)([H])O[C@]12O[C@@]4(CC[C@]([C@]5([H])O[C@@H](C)[C@](CC)(O)CC5)(C)O4)[C@H](O)C=C1
Properties
C42H70O11
Molar mass 751.011 g·mol−1
Pharmacology
QP51BB01 ( WHO )
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)

Salinomycin is an antibacterial and coccidiostat ionophore therapeutic drug.

Contents

Antibacterial activity

Salinomycin and its derivatives exhibit high antimicrobial activity against Gram-positive bacteria, including the most problematic bacteria strains such as methicillin-resistant Staphylococcus aureus and methicillin-resistant Staphylococcus epidermidis, and Mycobacterium tuberculosis . Salinomycin is inactive against fungi such as Candida and Gram-negative bacteria. [1]

Cancer research

Pre-clinical

Salinomycin has been shown by Piyush Gupta et al. of the Massachusetts Institute of Technology and the Broad Institute to kill breast cancer stem cells in mice at least 100 times more effectively than the anti-cancer drug paclitaxel. The study screened 16,000 different chemical compounds and found that only a small subset, including salinomycin and etoposide, targeted cancer stem cells responsible for metastasis and relapse. [2] [3] [4] [5]

The mechanism of action by which salinomycin kills cancer stem cells involves lysosomal iron sequestration, leading to the production of reactive oxygen species, lysosome membrane permeabilization and ferroptosis. [6] Studies performed in 2011 showed that salinomycin could induce apoptosis of human cancer cells at higher concentrations. C20 amino derivatives such as ironomycin have shown to be more potent in vitro models of persister cancer cells and in vivo doi : 10.1038/nchem.2778. Promising results from a few clinical pilot studies reveal that salinomycin is able to effectively eliminate cancer stem cells and to induce partial clinical regression of heavily pretreated and therapy-resistant cancers. The ability of salinomycin to kill both cancer stem cells and therapy-resistant cancer cells (persister) may define the compound as a novel and an effective anticancer drug. [7] [8] It has been also shown that salinomycin and its derivatives exhibit potent antiproliferative activity against the drug-resistant cancer cell lines. [9] [10] Salinomycin is the key compound in the pharmaceutical company Verastem's efforts to produce an anti-cancer-stem-cell drug.[ citation needed ]

Use in agriculture

Salinomycin is used in chicken feed as a coccidiostat.[ citation needed ]

Biosynthesis

A team from the University of Cambridge has cloned and sequenced the biosynthetic cluster responsible for salinomycin production, from Streptomyces albus DSM 41398. [11] This has shown that the polyketide backbone of salinomycin is synthesised on an assembly line of nine polyketide synthase) multienzymes. Furthermore, the cluster contains genes involved in oxidative cyclization including salC (epoxidase) and salBI/BII/BIII (epoxide hydrolase) genes. The cluster also contains genes suspected to be involved in self-resistance, export, precursor supply and regulation. The cluster contains a NRPS[ clarification needed ]-like carrier protein, SalX, that is suspected to tether “pre-salinomycin” during oxidative cyclization. By inactivating salC the researchers have demonstrated that salinomycin biosynthesis proceeds via a diene intermediate.[ citation needed ]

See also

Related Research Articles

<span class="mw-page-title-main">Phenothiazine</span> Heterocyclic compound containing a ring of four carbon, one nitrogen and one sulfur atom

Phenothiazine, abbreviated PTZ, is an organic compound that has the formula S(C6H4)2NH and is related to the thiazine-class of heterocyclic compounds. Derivatives of phenothiazine are highly bioactive and have widespread use and rich history.

<span class="mw-page-title-main">Sirolimus</span> Pharmaceutical drug

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mechanistic target of rapamycin kinase (mTOR) inhibitor that inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2).

In organic chemistry, polyketides are a class of natural products derived from a precursor molecule consisting of a chain of alternating ketone and methylene groups: [−C(=O)−CH2−]n. First studied in the early 20th century, discovery, biosynthesis, and application of polyketides has evolved. It is a large and diverse group of secondary metabolites caused by its complex biosynthesis which resembles that of fatty acid synthesis. Because of this diversity, polyketides can have various medicinal, agricultural, and industrial applications. Many polyketides are medicinal or exhibit acute toxicity. Biotechnology has enabled discovery of more naturally-occurring polyketides and evolution of new polyketides with novel or improved bioactivity.

<span class="mw-page-title-main">Chalcone</span> Chemical compound

Chalcone is the organic compound C6H5C(O)CH=CHC6H5. It is an α,β-unsaturated ketone. A variety of important biological compounds are known collectively as chalcones or chalconoids. They are widely known bioactive substances, fluorescent materials, and chemical intermediates.

<span class="mw-page-title-main">Ionophore</span> Chemical entity that reversibly binds ions

In chemistry, an ionophore is a chemical species that reversibly binds ions. Many ionophores are lipid-soluble entities that transport ions across the cell membrane. Ionophores catalyze ion transport across hydrophobic membranes, such as liquid polymeric membranes or lipid bilayers found in the living cells or synthetic vesicles (liposomes). Structurally, an ionophore contains a hydrophilic center and a hydrophobic portion that interacts with the membrane.

Quinazoline is an organic compound with the formula C8H6N2. It is an aromatic heterocycle with a bicyclic structure consisting of two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring. It is a light yellow crystalline solid that is soluble in water. Also known as 1,3-diazanaphthalene, quinazoline received its name from being an aza derivative of quinoline. Though the parent quinazoline molecule is rarely mentioned by itself in technical literature, substituted derivatives have been synthesized for medicinal purposes such as antimalarial and anticancer agents. Quinazoline is a planar molecule. It is isomeric with the other diazanaphthalenes of the benzodiazine subgroup: cinnoline, quinoxaline, and phthalazine. Over 200 biologically active quinazoline and quinoline alkaloids are identified.

<span class="mw-page-title-main">Tigecycline</span> Chemical compound

Tigecycline, sold under the brand name Tygacil, is a tetracycline antibiotic medication for a number of bacterial infections. It is a glycylcycline administered intravenously. It was developed in response to the growing rate of antibiotic resistant bacteria such as Staphylococcus aureus, Acinetobacter baumannii, and E. coli. As a tetracycline derivative antibiotic, its structural modifications has expanded its therapeutic activity to include Gram-positive and Gram-negative organisms, including those of multi-drug resistance.

<span class="mw-page-title-main">Podophyllotoxin</span> Chemical compound

Podophyllotoxin (PPT) is the active ingredient in Podofilox, which is a medical cream that is used to treat genital warts and molluscum contagiosum. It is not recommended in HPV infections without external warts. It can be applied either by a healthcare provider or the person themselves.

<span class="mw-page-title-main">Tirapazamine</span> Chemical compound

Tirapazamine (SR-[[4233]]) is an experimental anticancer drug that is activated to a toxic radical only at very low levels of oxygen (hypoxia). Such levels are common in human solid tumors, a phenomenon known as tumor hypoxia. Thus, tirapazamine is activated to its toxic form preferentially in the hypoxic areas of solid tumors. Cells in these regions are resistant to killing by radiotherapy and most anticancer drugs. Thus the combination of tirapazamine with conventional anticancer treatments is particularly effective. As of 2006, tirapazamine is undergoing phase III testing in patients with head and neck cancer and gynecological cancer, and similar trials are being undertaken for other solid tumor types.

<span class="mw-page-title-main">A23187</span> Chemical compound

A23187 is a mobile ion-carrier that forms stable complexes with divalent cations. A23187 is also known as Calcimycin, Calcium Ionophore, Antibiotic A23187 and Calcium Ionophore A23187. It is produced at fermentation of Streptomyceschartreusensis.

Topoisomerase inhibitors are chemical compounds that block the action of topoisomerases, which are broken into two broad subtypes: type I topoisomerases (TopI) and type II topoisomerases (TopII). Topoisomerase plays important roles in cellular reproduction and DNA organization, as they mediate the cleavage of single and double stranded DNA to relax supercoils, untangle catenanes, and condense chromosomes in eukaryotic cells. Topoisomerase inhibitors influence these essential cellular processes. Some topoisomerase inhibitors prevent topoisomerases from performing DNA strand breaks while others, deemed topoisomerase poisons, associate with topoisomerase-DNA complexes and prevent the re-ligation step of the topoisomerase mechanism. These topoisomerase-DNA-inhibitor complexes are cytotoxic agents, as the un-repaired single- and double stranded DNA breaks they cause can lead to apoptosis and cell death. Because of this ability to induce apoptosis, topoisomerase inhibitors have gained interest as therapeutics against infectious and cancerous cells.

<span class="mw-page-title-main">Cecropin</span>

Cecropins are antimicrobial peptides. They were first isolated from the hemolymph of Hyalophora cecropia, whence the term cecropin was derived. Cecropins lyse bacterial cell membranes; they also inhibit proline uptake and cause leaky membranes.

<span class="mw-page-title-main">Halichondrin B</span> Chemical compound

Halichondrin B is a polyether macrolide originally isolated from the marine sponge Halichondria okadai by Hirata and Uemura in 1986. In the same report, these authors also reported the exquisite anticancer activity of halichondrin B against murine cancer cells both in culture and in in vivo studies. Halichondrin B was highly prioritized for development as a novel anticancer therapeutic by the United States National Cancer Institute and, in 1991, was the original test case for identification of mechanism of action by NCI's then-brand-new "60-cell line screen" The complete chemical synthesis of halichondrin B was achieved by Yoshito Kishi and colleagues at Harvard University in 1992, an achievement that ultimately enabled the discovery and development of the structurally simplified and pharmaceutically optimized analog eribulin. Eribulin was approved by the U.S. Food and Drug Administration on November 15, 2010, to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies. Eribulin is marketed by Eisai Co. under the tradename Halaven.

Bcr-Abl tyrosine-kinase inhibitors (TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality was discovered by Peter Nowell in 1960 and is a consequence of fusion between the Abelson (Abl) tyrosine kinase gene at chromosome 9 and the break point cluster (Bcr) gene at chromosome 22, resulting in a chimeric oncogene (Bcr-Abl) and a constitutively active Bcr-Abl tyrosine kinase that has been implicated in the pathogenesis of CML. Compounds have been developed to selectively inhibit the tyrosine kinase.

<span class="mw-page-title-main">Temozolomide</span> Cancer medication

Temozolomide, sold under the brand name Temodar among others, is an anticancer medication used to treat brain tumors such as glioblastoma and anaplastic astrocytoma. It is taken by mouth or via intravenous infusion.

Tubulin inhibitors are chemotherapy drugs that interfere directly with the tubulin system, which is in contrast to those chemotherapy drugs acting on DNA. Microtubules play an important role in eukaryotic cells. Alpha- and beta-tubulin, the main components of microtubules, have gained considerable interest because of their function and biophysical properties and has become the subject of intense study.

<span class="mw-page-title-main">Titanocene Y</span>

Titanocene Y also known as bis[(p-methoxybenzyl)cyclopentadienyl]titanium(IV) dichloride or dichloridobis(η5-(p-methoxybenzyl)cyclopentadienyl)titanium is an organotitanium compound that has been investigated for use as an anticancer drug.

<span class="mw-page-title-main">C-1027</span> Chemical compound

C-1027 or lidamycin is an antitumor antibiotic consisting of a complex of an enediyne chromophore and an apoprotein. It shows antibiotic activity against most Gram-positive bacteria. It is one of the most potent cytotoxic molecules known, due to its induction of a higher ratio of DNA double-strand breaks than single-strand breaks.

<span class="mw-page-title-main">Ironomycin</span> Chemical compound

Ironomycin is a derivative of salinomycin and potent small molecule against persister cancer stem cells, that is under preclinical evaluation by SideROS for the treatment of cancer. Ironomycin was shown to induce ferroptosis in breast cancer cell lines and its mechanism of action involves the targeting of lysosomal iron.

Colibactin is a genotoxic metabolite produced by Escherichia coli and other Enterobacteriaceae believed to cause mutations leading to colorectal cancer and the progression of colorectal cancer. Colibactin is a polyketide peptide that can form interstrand crosslinks in DNA. Colibactin is only produced by bacterial strains containing a polyketide synthase genomic island (pks) or clb biosynthetic gene cluster. About 20% of humans are colonized with E. coli that harbor the pks island.

References

  1. M. Antoszczak; et al. (2014). "Synthesis, Anticancer and Antibacterial Activity of Salinomycin N-Benzyl Amides". Molecules . 19 (12): 19435–19459. doi: 10.3390/molecules191219435 . PMC   6271077 . PMID   25429565.
  2. "Drug shows cancer stem cells not invulnerable". New Scientist. 2009-08-13.
  3. "New method takes aim at aggressive cancer cells". Broad Communications. Broad Institute. 2009-08-13. Retrieved 2009-08-13.
  4. Gupta, P.; Onder, Tamer T.; Jiang, Guozhi; Tao, Kai; Kuperwasser, Charlotte; Weinberg, Robert A.; Lander, Eric S.; et al. (2009-08-13). "Identification of selective inhibitors of cancer stem cells by high-throughput screening". Cell . 138 (4): 645–59. doi:10.1016/j.cell.2009.06.034. PMC   4892125 . PMID   19682730.
  5. Adam Huczynski (2012). "Salinomycin – a New Cancer Drug Candidate". Chemical Biology & Drug Design . 79 (3): 235–238. doi:10.1111/j.1747-0285.2011.01287.x. PMID   22145602. S2CID   40843415.
  6. Mai, Trang Thi; Hamaï, Ahmed; Hienzsch, Antje; Cañeque, Tatiana; Müller, Sebastian; Wicinski, Julien; Cabaud, Olivier; Leroy, Christine; David, Amandine; Acevedo, Verónica; Ryo, Akihide; Ginestier, Christophe; Birnbaum, Daniel; Charafe-Jauffret, Emmanuelle; Codogno, Patrice; Mehrpour, Maryam; xRodriguez, Raphaël Rodriguez (Oct 2017). "Salinomycin kills cancer stem cells by sequestering iron in lysosomes". Nature Chemistry. 9 (10): 1025–1033. Bibcode:2017NatCh...9.1025M. doi:10.1038/nchem.2778. PMC   5890907 . PMID   28937680.
  7. C. Naujokat, R. Steinhart "Salinomycin as a Drug for Targeting Human Cancer Stem Cells”, Journal of Biomedicine and Biotechnology , Volume 2012 (2012), Article ID 950658, doi : 10.1155/2012/950658, open access review article
  8. A. Huczyński, ”Polyether ionophores—promising bioactive molecules for cancer therapy”, Bioorganic & Medicinal Chemistry Letters , 2012,22, 7002-7010, doi : 10.1016/j.bmcl.2012.09.046, open access review article
  9. A. Huczyński, J. Janczak, M. Antoszczak, J. Wietrzyk, E. Maj, B. Brzezinski, ” Antiproliferative activity of salinomycin and its derivatives”, Bioorganic & Medicinal Chemistry Letters , 2012, 22, 7146-7150, doi : 10.1016/j.bmcl.2012.09.068,
  10. Antoszczak, Michal; Huczynski, Adam (2015). "Anticancer Activity of Polyether Ionophore-Salinomycin". Anti-Cancer Agents in Medicinal Chemistry . 15 (5): 575–591. doi:10.2174/1871520615666150101130209. PMID   25553435. review article
  11. Yurkovich, Marie E.; Tyrakis, Petros A.; Hong, Hui; Sun, Yuhui; Samborskyy, Markiyan; Kamiya, Kohei; Leadlay, Peter F.; et al. (2011-11-11). "A Late-Stage Intermediate in Salinomycin Biosynthesis Is Revealed by Specific Mutation in the Biosynthetic Gene Cluster". ChemBioChem . 13 (1): 66–71. doi:10.1002/cbic.201100590. PMID   22076845. S2CID   22332727.